Table 3.
Distribution of cancer patients by stage of disease, tumor morphology, and gender in subgroups stratified by TF-specific antibody reactivity to SNA and anti-TF IgM level.
| Group of patients | n | SNA/IgM subgroup | |||
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | ||
| SNA≥IgM≥ | SNA<IgM≥ | SNA≥IgM< | SNA<IgM< | ||
| 124∗ | 25 | 37 | 36 | 26 | |
|
| |||||
| Stage 1 | 43 | 8 (18.6) | 14 (32.2) | 13 (30.2) | 8 (18.6) |
| Stage 2 | 28 | 7 (25.0) | 7 (25.0) | 8 (28.6) | 6 (21.4) |
| Stage 3 | 39 | 7 (17.9) | 13 (33.3) | 12 (30.7) | 7 (17.9) |
| Stage 4 | 14 | 3 (21.4) | 3 (21.4) | 3 (21.4) | 5 (35.7) |
|
| |||||
| DT | 49 | 11 (22.4) | 16 (32.7) | 14 (28.6) | 8 (16.3) |
| IT | 73 | 14 (19.2) | 19 (26.0) | 22 (30.1) | 18 (24.6) |
|
| |||||
| males | 70 | 15 (21.7) | 18 (25.7) | 20 (28.6) | 17 (24.3) |
| females | 54 | 10 (18.5) | 19 (35.2) | 16 (29.6) | 9 (16.7) |
*Two patients had morphologically mixed (unclassified) tumors.
In brackets: the percentage in the corresponding group.